Vasopressin Receptor Antagonists

Biff F. Palmer

doi:10.1007/s11906-014-0510-4

Vasopressin Receptor Antagonists

Biff F. Palmer

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

Arginine vasopressin (AVP) is the principal hormone involved in regulating the tonicity of body fluids. Less appreciated is the role that AVP plays in a variety of other physiologic functions including glucose metabolism, cardiovascular homeostasis, bone metabolism, and cognitive behavior. AVP receptor antagonists are now available and currently approved to treat hyponatremia. There is a great deal of interest in exploring the potential benefits that these drugs may play in blocking AVP-mediated effects in other organ systems. The purpose of this report is to provide an update on the expanding role of AVP receptor antagonists and what disease states these drugs may eventually be used for.

Original language	English (US)
Journal	Current hypertension reports
Volume	17
Issue number	1
DOIs	https://doi.org/10.1007/s11906-014-0510-4
State	Published - Jan 2015

Keywords

Aquaporin
Arginine vasopressin
Cirrhosis
Congestive heart failure
Conivaptan
Endolymphatic hydrops
Hyponatremia
Osteoporosis
Polycystic kidney disease
Potassium
Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Tolvaptan
Vasopressin receptor V1a
Vasopressin receptor V1b
Vasopressin receptor V2

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.1007/s11906-014-0510-4

Cite this

@article{de1215160b82419f831b70f998ba8dd0,

title = "Vasopressin Receptor Antagonists",

abstract = "Arginine vasopressin (AVP) is the principal hormone involved in regulating the tonicity of body fluids. Less appreciated is the role that AVP plays in a variety of other physiologic functions including glucose metabolism, cardiovascular homeostasis, bone metabolism, and cognitive behavior. AVP receptor antagonists are now available and currently approved to treat hyponatremia. There is a great deal of interest in exploring the potential benefits that these drugs may play in blocking AVP-mediated effects in other organ systems. The purpose of this report is to provide an update on the expanding role of AVP receptor antagonists and what disease states these drugs may eventually be used for.",

keywords = "Aquaporin, Arginine vasopressin, Cirrhosis, Congestive heart failure, Conivaptan, Endolymphatic hydrops, Hyponatremia, Osteoporosis, Polycystic kidney disease, Potassium, Syndrome of inappropriate antidiuretic hormone secretion (SIADH), Tolvaptan, Vasopressin receptor V1a, Vasopressin receptor V1b, Vasopressin receptor V2",

author = "Palmer, {Biff F.}",

note = "Publisher Copyright: {\textcopyright} 2015, Springer Science+Business Media New York.",

year = "2015",

month = jan,

doi = "10.1007/s11906-014-0510-4",

language = "English (US)",

volume = "17",

journal = "Current hypertension reports",

issn = "1522-6417",

publisher = "Current Medicine Group",

number = "1",

}

TY - JOUR

T1 - Vasopressin Receptor Antagonists

AU - Palmer, Biff F.

PY - 2015/1

Y1 - 2015/1

N2 - Arginine vasopressin (AVP) is the principal hormone involved in regulating the tonicity of body fluids. Less appreciated is the role that AVP plays in a variety of other physiologic functions including glucose metabolism, cardiovascular homeostasis, bone metabolism, and cognitive behavior. AVP receptor antagonists are now available and currently approved to treat hyponatremia. There is a great deal of interest in exploring the potential benefits that these drugs may play in blocking AVP-mediated effects in other organ systems. The purpose of this report is to provide an update on the expanding role of AVP receptor antagonists and what disease states these drugs may eventually be used for.

AB - Arginine vasopressin (AVP) is the principal hormone involved in regulating the tonicity of body fluids. Less appreciated is the role that AVP plays in a variety of other physiologic functions including glucose metabolism, cardiovascular homeostasis, bone metabolism, and cognitive behavior. AVP receptor antagonists are now available and currently approved to treat hyponatremia. There is a great deal of interest in exploring the potential benefits that these drugs may play in blocking AVP-mediated effects in other organ systems. The purpose of this report is to provide an update on the expanding role of AVP receptor antagonists and what disease states these drugs may eventually be used for.

KW - Aquaporin

KW - Arginine vasopressin

KW - Cirrhosis

KW - Congestive heart failure

KW - Conivaptan

KW - Endolymphatic hydrops

KW - Hyponatremia

KW - Osteoporosis

KW - Polycystic kidney disease

KW - Potassium

KW - Syndrome of inappropriate antidiuretic hormone secretion (SIADH)

KW - Tolvaptan

KW - Vasopressin receptor V1a

KW - Vasopressin receptor V1b

KW - Vasopressin receptor V2

UR - http://www.scopus.com/inward/record.url?scp=84940040450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940040450&partnerID=8YFLogxK

U2 - 10.1007/s11906-014-0510-4

DO - 10.1007/s11906-014-0510-4

M3 - Review article

C2 - 25604388

AN - SCOPUS:84940040450

SN - 1522-6417

VL - 17

JO - Current hypertension reports

JF - Current hypertension reports

IS - 1

ER -

Vasopressin Receptor Antagonists

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this